About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Our lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. RP-G28 has been studied in Phase 2 trials and is now in Phase 3 clinical development. We are further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease.

 

picture

  • Ritter’s medical advisory board represents the world’s experts in lactose intolerance
  • Worldwide more than 1 billion people suffer from lactose intolerance
  • Read more about lactose intolerance

Learn More

picture

  • A breakthrough treatment aiming to eradicate symptoms of lactose intolerance
  • Potential to become the first FDA-approved treatment for lactose intolerance
  • Studied in Phase 2 trials

About RP-G38

Latest News
Latest News
Latest News

Featuring Recent Posts WordPress Widget development by YD